Johnson & Johnson receives permanent billing code for bladder cancer treatment
Go back to Johnson & Johnson receives permanent billing code for bladder cancer treatment| Johnson & Johnson (NYSE: JNJ) | Delayed: 228.17 +4.93 (2.21%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $223.24 | 52 Week High | $126.07 | |||
| Open | $227.09 | 52 Week Low | $94.28 | |||
| Day High | $228.67 | P/E | 47.44 | |||
| Day Low | $225.90 | EPS | $4.81 | |||
| Volume | 7,274,160 | |||||

